Preliminary and ongoing French multicenter prospective naturalistic study of adverse events of antipsychotic treatment in naive children and adolescents

[1] Wong IC(2004)Increased prescribing trends of paediatric psychotropic medications Arch Dis Child 89 1131-1132

[2] Murray ML(2012)Panorama de la prescription et de la consommation des psychotropes chez l’enfant et l’adolescent en France Neuropsychiatr Enf Adolesc 60 77-85

[3] Camilleri-Novak D(2005)Trends in the use of typical and atypical antipsychotics in children and adolescents J Am Acad Child Adolesc Psychiatry 44 548-556

[4] Stephens P(2008)Efficacy and tolerability of second-generation antipsychotics in children and adolescents with schizophrenia Schizophr Bull 34 60-71

[5] Acquaviva E(2012)Antipsychotic medication prescribing trends in children and adolescents J Pediatr Health Care 2 139-145

[6] Peyre H(2009)Antipsychotics in children and adolescents: Increasing use, evidence for efficacy and safety concerns Eur Neuropsychopharmocol 19 629-635

[7] Falissard B(2012)The relationship between mental health diagnosis and treatment with second-generation antipsychotics over time: a national study of U.S. Medicaid-enrolled children Health Serv Res 47 1836-1860

[8] Patel NC(2011)Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons Eur Neuropsychopharmacol 21 621-645

[9] Crismon ML(2011)Second generation antipsychotics (SGAs) for non-psychotic disorders in children and adolescents: a review of the randomized controlled studies Eur Neuropsychopharmacol 21 600-620

[10] Hoagwood K(2012)Utilisation des antipsychotiques chez l’enfant et l’adolescent Neuropsychiatr Enf Adolesc 60 12-19

[1] Wong IC(2004)Increased prescribing trends of paediatric psychotropic medications Arch Dis Child 89 1131-1132

[2] Murray ML(2012)Panorama de la prescription et de la consommation des psychotropes chez l’enfant et l’adolescent en France Neuropsychiatr Enf Adolesc 60 77-85

[3] Camilleri-Novak D(2005)Trends in the use of typical and atypical antipsychotics in children and adolescents J Am Acad Child Adolesc Psychiatry 44 548-556

[4] Stephens P(2008)Efficacy and tolerability of second-generation antipsychotics in children and adolescents with schizophrenia Schizophr Bull 34 60-71

[5] Acquaviva E(2012)Antipsychotic medication prescribing trends in children and adolescents J Pediatr Health Care 2 139-145

[6] Peyre H(2009)Antipsychotics in children and adolescents: Increasing use, evidence for efficacy and safety concerns Eur Neuropsychopharmocol 19 629-635

[7] Falissard B(2012)The relationship between mental health diagnosis and treatment with second-generation antipsychotics over time: a national study of U.S. Medicaid-enrolled children Health Serv Res 47 1836-1860

[8] Patel NC(2011)Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons Eur Neuropsychopharmacol 21 621-645

[9] Crismon ML(2011)Second generation antipsychotics (SGAs) for non-psychotic disorders in children and adolescents: a review of the randomized controlled studies Eur Neuropsychopharmacol 21 600-620

[10] Hoagwood K(2012)Utilisation des antipsychotiques chez l’enfant et l’adolescent Neuropsychiatr Enf Adolesc 60 12-19